197 related articles for article (PubMed ID: 20818424)
1. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis.
Lacher MD; Pincheira R; Zhu Z; Camoretti-Mercado B; Matli M; Warren RS; Castro AF
Oncogene; 2010 Dec; 29(50):6543-56. PubMed ID: 20818424
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
[TBL] [Abstract][Full Text] [Related]
3. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
[TBL] [Abstract][Full Text] [Related]
5. Consequences of interrupted Rheb-to-AMPK feedback signaling in tuberous sclerosis complex and cancer.
Lacher MD; Pincheira RJ; Castro AF
Small GTPases; 2011 Jul; 2(4):211-216. PubMed ID: 22145093
[TBL] [Abstract][Full Text] [Related]
6. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
[TBL] [Abstract][Full Text] [Related]
7. Measurements of TSC2 GAP activity toward Rheb.
Li Y; Inoki K; Vikis H; Guan KL
Methods Enzymol; 2006; 407():46-54. PubMed ID: 16757313
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
[TBL] [Abstract][Full Text] [Related]
9. p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb.
Agarwal S; Bell CM; Taylor SM; Moran RG
Mol Cancer Res; 2016 Jan; 14(1):66-77. PubMed ID: 26385560
[TBL] [Abstract][Full Text] [Related]
10. Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity.
Carroll B; Maetzel D; Maddocks OD; Otten G; Ratcliff M; Smith GR; Dunlop EA; Passos JF; Davies OR; Jaenisch R; Tee AR; Sarkar S; Korolchuk VI
Elife; 2016 Jan; 5():. PubMed ID: 26742086
[TBL] [Abstract][Full Text] [Related]
11. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway.
Yoshida S; Hong S; Suzuki T; Nada S; Mannan AM; Wang J; Okada M; Guan KL; Inoki K
J Biol Chem; 2011 Sep; 286(37):32651-60. PubMed ID: 21784859
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth.
Wang Y; Hong X; Wang J; Yin Y; Zhang Y; Zhou Y; Piao HL; Liang Z; Zhang L; Li G; Xu G; Kwiatkowski DJ; Liu Y
Oncogene; 2017 Feb; 36(6):756-765. PubMed ID: 27399332
[TBL] [Abstract][Full Text] [Related]
13. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
Zhang Y; Gao X; Saucedo LJ; Ru B; Edgar BA; Pan D
Nat Cell Biol; 2003 Jun; 5(6):578-81. PubMed ID: 12771962
[TBL] [Abstract][Full Text] [Related]
14. Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex.
Yasuda S; Sugiura H; Katsurabayashi S; Shimada T; Tanaka H; Takasaki K; Iwasaki K; Kobayashi T; Hino O; Yamagata K
Sci Rep; 2014 Jun; 4():5155. PubMed ID: 24889507
[TBL] [Abstract][Full Text] [Related]
15. Regulation of folliculin (the BHD gene product) phosphorylation by Tsc2-mTOR pathway.
Piao X; Kobayashi T; Wang L; Shiono M; Takagi Y; Sun G; Abe M; Hagiwara Y; Zhang D; Okimoto K; Kouchi M; Matsumoto I; Hino O
Biochem Biophys Res Commun; 2009 Nov; 389(1):16-21. PubMed ID: 19695222
[TBL] [Abstract][Full Text] [Related]
16. Rheb binds and regulates the mTOR kinase.
Long X; Lin Y; Ortiz-Vega S; Yonezawa K; Avruch J
Curr Biol; 2005 Apr; 15(8):702-13. PubMed ID: 15854902
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1.
Zheng M; Wang YH; Wu XN; Wu SQ; Lu BJ; Dong MQ; Zhang H; Sun P; Lin SC; Guan KL; Han J
Nat Cell Biol; 2011 Mar; 13(3):263-72. PubMed ID: 21336308
[TBL] [Abstract][Full Text] [Related]
18. PDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade.
Liu Z; Chen X; Wang Y; Peng H; Wang Y; Jing Y; Zhang H
J Biol Chem; 2014 Oct; 289(43):29739-49. PubMed ID: 25164809
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
20. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation.
Uhlmann EJ; Li W; Scheidenhelm DK; Gau CL; Tamanoi F; Gutmann DH
Glia; 2004 Aug; 47(2):180-8. PubMed ID: 15185396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
